Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Prostatic Neoplasms 8Neuroendocrine Tumors 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Lymphoma, Non-Hodgkin 2Lymphoma 2Disease 2Brain Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Vasculitis 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Stomach Neoplasms 1Solid Tumor, Adult 1Smoking Cessation 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Papillomavirus Infections 1Pancreatic Neoplasms 1Pancreatic Cystic Neoplasms 1Osteomyelitis 1Nose Neoplasms 1Neurodegenerative Diseases 1Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multiple Pulmonary Nodules 1

Interventions

Cyclophosphamide 118Peripheral Blood Stem Cell Transplantation 67Filgrastim 60Etoposide 60Rituximab 54fludarabine phosphate 50Vincristine 46Radiotherapy 46Methotrexate 46Cytarabine 44Doxorubicin 40Cyclosporine 35Mycophenolic Acid 33Busulfan 33Prednisone 32Whole-Body Irradiation 31Tacrolimus 28Antilymphocyte Serum 28Melphalan 27Dexamethasone 26Methylprednisolone 22Leucovorin 19Carmustine 18Granulocyte Colony-Stimulating Factor 17Calcium Dobesilate 16Ifosfamide 15Psychiatric Rehabilitation 13Cord Blood Stem Cell Transplantation 13sargramostim 12merphos 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Burkitt Lymphoma × Positron-Emission Tomography × Clear all
NCT00001337 2025-06-22

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
348 enrolled 15 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡